Sarepta (SRPT) plans to continue Elevidys shipments for Duchenne muscular dystrophy, despite FDA request not to do so after ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today issued the ...

As of July 18, 2025, the Food and Drug Administration (FDA) said it has received three reports of fatal acute liver failure ...

U.S. stocks ended the week mostly higher, with the S&P 500 (+0.6%) and Nasdaq (+1.5%) setting new record highs, lifted by strong Q2 earnings and softer-than-expected inflation data. June retail sales ...

Here are Investing.com’s stocks of the week. CRCL rallied, with the stock boosted by news that the U.S. House of ...

One of biotech’s highest fliers, Sarepta Therapeutics, lost more than a third of its market value on Friday after executives said that one of its experimental gene-replacement therapies was linked to ...